These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 35214646)

  • 41. Human Papillomavirus (HPV) Genotyping Assay Suitable for Monitoring the Impact of the 9-Valent HPV Vaccine.
    Kukimoto I; Matsumoto K; Takahashi F; Iwata T; Tanaka K; Yamaguchi-Naka M; Yamamoto K; Yahata H; Nakabayashi M; Kato H; Tsuda N; Onuki M; Yaegashi N;
    Tohoku J Exp Med; 2020 Aug; 251(4):287-294. PubMed ID: 32759554
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human papillomavirus genotype contribution to cervical cancer and precancer: Implications for screening and vaccination in Japan.
    Onuki M; Matsumoto K; Iwata T; Yamamoto K; Aoki Y; Maenohara S; Tsuda N; Kamiura S; Takehara K; Horie K; Tasaka N; Yahata H; Takei Y; Aoki Y; Kato H; Motohara T; Nakamura K; Ishikawa M; Kato T; Yoshida H; Matsumura N; Nakai H; Shigeta S; Takahashi F; Noda K; Yaegashi N; Yoshikawa H
    Cancer Sci; 2020 Jul; 111(7):2546-2557. PubMed ID: 32372453
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduction in HPV16/18 prevalence among young women with high-grade cervical lesions following the Japanese HPV vaccination program.
    Matsumoto K; Yaegashi N; Iwata T; Yamamoto K; Aoki Y; Okadome M; Ushijima K; Kamiura S; Takehara K; Horie K; Tasaka N; Sonoda K; Takei Y; Aoki Y; Konnai K; Katabuchi H; Nakamura K; Ishikawa M; Watari H; Yoshida H; Matsumura N; Nakai H; Shigeta S; Takahashi F; Noda K; Yoshikawa H;
    Cancer Sci; 2019 Dec; 110(12):3811-3820. PubMed ID: 31596999
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
    Drolet M; Bénard É; Pérez N; Brisson M;
    Lancet; 2019 Aug; 394(10197):497-509. PubMed ID: 31255301
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.
    Woestenberg PJ; Bogaards JA; King AJ; Leussink S; van der Sande MA; Hoebe CJ; van Benthem BH;
    Int J Cancer; 2019 Jun; 144(11):2718-2727. PubMed ID: 30426502
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection.
    Kudo R; Yamaguchi M; Sekine M; Adachi S; Ueda Y; Miyagi E; Hara M; Hanley SJB; Enomoto T
    J Infect Dis; 2019 Jan; 219(3):382-390. PubMed ID: 30299519
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential misclassification between self-reported status and official HPV vaccination records in Japan: Implications for evaluating vaccine safety and effectiveness.
    Yamaguchi M; Sekine M; Kudo R; Adachi S; Ueda Y; Miyagi E; Hara M; Hanley SJB; Enomoto T
    Papillomavirus Res; 2018 Dec; 6():6-10. PubMed ID: 29807210
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of HPV vaccination against high grade cervical lesions in Japan.
    Konno R; Konishi H; Sauvaget C; Ohashi Y; Kakizoe T
    Vaccine; 2018 Dec; 36(52):7913-7915. PubMed ID: 29778520
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dynamic changes in Japan's prevalence of abnormal findings in cervical cervical cytology depending on birth year.
    Ueda Y; Yagi A; Nakayama T; Hirai K; Ikeda S; Sekine M; Miyagi E; Enomoto T
    Sci Rep; 2018 Apr; 8(1):5612. PubMed ID: 29618795
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.
    Woestenberg PJ; King AJ; van Benthem BHB; Donken R; Leussink S; van der Klis FRM; de Melker HE; van der Sande MAB; Hoebe CJPA; Bogaards JA;
    J Infect Dis; 2018 Jan; 217(2):213-222. PubMed ID: 29140439
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014.
    Oliver SE; Unger ER; Lewis R; McDaniel D; Gargano JW; Steinau M; Markowitz LE
    J Infect Dis; 2017 Sep; 216(5):594-603. PubMed ID: 28931217
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preventive effect of human papillomavirus vaccination on the development of uterine cervical lesions in young Japanese women.
    Tanaka H; Shirasawa H; Shimizu D; Sato N; Ooyama N; Takahashi O; Terada Y
    J Obstet Gynaecol Res; 2017 Oct; 43(10):1597-1601. PubMed ID: 28707725
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early impact of the Japanese immunization program implemented before the HPV vaccination crisis.
    Matsumoto K; Yaegashi N; Iwata T; Yamamoto K; Nagashima M; Saito T; Ushijima K; Takahashi F; Noda K; Yoshikawa H
    Int J Cancer; 2017 Oct; 141(8):1704-1706. PubMed ID: 28657110
    [No Abstract]   [Full Text] [Related]  

  • 54. Realistic fear of cervical cancer risk in Japan depending on birth year.
    Yagi A; Ueda Y; Egawa-Takata T; Tanaka Y; Nakae R; Morimoto A; Terai Y; Ohmichi M; Ichimura T; Sumi T; Murata H; Okada H; Nakai H; Mandai M; Matsuzaki S; Kobayashi E; Yoshino K; Kimura T; Saito J; Hori Y; Morii E; Nakayama T; Suzuki Y; Motoki Y; Sukegawa A; Asai-Sato M; Miyagi E; Yamaguchi M; Kudo R; Adachi S; Sekine M; Enomoto T; Horikoshi Y; Takagi T; Shimura K
    Hum Vaccin Immunother; 2017 Jul; 13(7):1700-1704. PubMed ID: 28272968
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Beneficial Effects of Human Papillomavirus Vaccine for Prevention of Cervical Abnormalities in Miyagi, Japan.
    Ozawa N; Ito K; Tase T; Metoki H; Yaegashi N
    Tohoku J Exp Med; 2016 Oct; 240(2):147-151. PubMed ID: 27746423
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HPV vaccination crisis in Japan.
    Hanley SJ; Yoshioka E; Ito Y; Kishi R
    Lancet; 2015 Jun; 385(9987):2571. PubMed ID: 26122153
    [No Abstract]   [Full Text] [Related]  

  • 57. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
    Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
    Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monitoring the impact of a national HPV vaccination program in Japan (MINT Study): rationale, design and methods.
    Matsumoto K; Yaegashi N; Iwata T; Ariyoshi K; Fujiwara K; Shiroyama Y; Usami T; Kawano Y; Horie K; Kawano K; Noda K; Yoshikawa H;
    Jpn J Clin Oncol; 2014 Oct; 44(10):1000-3. PubMed ID: 25098705
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Self-report compared to electronic medical record across eight adult vaccines: do results vary by demographic factors?
    Rolnick SJ; Parker ED; Nordin JD; Hedblom BD; Wei F; Kerby T; Jackson JM; Crain AL; Euler G
    Vaccine; 2013 Aug; 31(37):3928-35. PubMed ID: 23806243
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer.
    Onuki M; Matsumoto K; Satoh T; Oki A; Okada S; Minaguchi T; Ochi H; Nakao S; Someya K; Yamada N; Hamada H; Yoshikawa H
    Cancer Sci; 2009 Jul; 100(7):1312-6. PubMed ID: 19432906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.